<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58784">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02012634</url>
  </required_header>
  <id_info>
    <org_study_id>TPYS-01</org_study_id>
    <nct_id>NCT02012634</nct_id>
  </id_info>
  <brief_title>A Multi-center, III Phase，Randomized Controlled Clinical Study of Capecitabine Beats Chemotherapy After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer</brief_title>
  <acronym>WUJING</acronym>
  <official_title>A Multi-center, III Phase，Randomized Controlled Clinical Study of Capecitabine Beats Chemotherapy After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multi-center, III Phase，Randomized Controlled Clinical Study of Capecitabine Beats
      Chemotherapy After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>PFS（Progression-free survival）</measure>
    <time_frame>Progression-free survival：time from the date of randomization until the date of disease progression，assessed up to 3 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>PFS was defined as the time from the date of randomization until the date of disease progression at any site including distant metastasis or second primary tumors or death， assessed up to 3 years</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Capecitabine</condition>
  <condition>TNBC</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Breast cancer patients of vascular endocrine surgery department in Xijing Hospital
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female;

          -  aged 18 - 70 years old;

          -  Histological confirmed with unilateral invasive carcinoma (all pathological types are
             applicable);

          -  Newly diagnosed conditions allowing direct surgery without any absolute
             contraindication for surgery;

          -  No mass or microscopic tumor residue after surgery resection;

          -  Initiate adjuvant chemotherapy within 30 days after surgery;

          -  Axillary lymph node positive (including the sentinel lymph node positive and lymph
             node positive after axillary dissection), for example, axillary lymph node negative
             requires that primary tumor size must be greater than 1cm;

          -  Definite reports on ER/PR(progesterone receptor)/Her2 receptor showing all ER/PR/Her2
             negative (specific definitions: immunohistochemical detection of ER &lt;10% tumor cells
             is defined as ER negative, PR &lt;10% positive tumor cells is defined as PR-negative,
             Her2 is 0~1+ or 2+ but determined negative via FISH or CISH detected (no
             amplification) is defined as Her2 negative);

          -  No relevant clinical or imaging evidence of metastasis showing in the preoperative
             examination (M0);

          -  Without peripheral neuropathy;

          -  ECOG performance score is 0 or 1;

          -  Postoperative recovery was good and an interval of at least one week since the
             surgery is necessary;

          -  White blood cell count&gt; 4 × 10^9/l, neutrophil count&gt; 2 × 10^9/l, platelet count&gt; 100
             × 10^9/l and hemoglobin 9g/dl);

          -  ASAT and ALAT &lt;1.5 folds of the upper limit of normal values, alkaline phosphatase
             &lt;2.5 folds of the upper limit of normal values, total bilirubin &lt;1.5 folds of the
             upper limit of normal values;

          -  Serum creatinine &lt;1.5 folds of the upper limit of normal value;

          -  Women at childbearing age should take contraception measures during treatment;

          -  Cardiac function: echocardiographic examination showed LEVF&gt; 50%;

          -  Informed consent form signed.

        Exclusion Criteria:

          -  Bilateral breast cancer or carcinoma in situ (DCIS / LCIS);

          -  Metastasis at any location;

          -  Any tumor &gt; T4a (UICC1987) (accompanied by skin involvement, lump adhesion and
             fixation, inflammatory breast cancer);

          -  Any of ER, PR or Her-2 is positive;

          -  Contralateral breast clinically or radiologically suspected to be malignant but not
             confirmed which needs a biopsy;

          -  Previous neoadjuvant therapy, including chemotherapy, radiotherapy and hormone
             therapy;

          -  Previously suffering from malignant tumors (except for basal cell carcinoma and
             cervical carcinoma in situ), including contralateral breast cancer;

          -  Already enrolled into other clinical trials;

          -  Severe systemic disease and/or uncontrollable infection, unable to be enrolled in
             this study LEVF &lt;50% (echocardiography);

          -  Suffering from severe cardiovascular and cerebrovascular diseases within six months
             before the randomization (such as: unstable angina, chronic heart failure,
             uncontrollable high blood  pressure &gt; 150/90mmHg, myocardial infarction or brain
             vascular accident);

          -  Known allergic to taxane and anthracycline agents;

          -  Women at childbearing age refuse to take contraception measures during the treatment
             and 8 weeks after completion of treatment;

          -  Pregnant and breast-feeding women;

          -  Pregnancy test showed positive results before drug administration after enrolling in
             to the study; With mental illness and cognitive impairment, unable to understand
             trial protocol and side effects and complete trial protocol and follow-ups
             (systematic evaluation is required before recruiting into this study);

          -  Without personal freedom and independent civil capacity.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hongliang Wei, Mster</last_name>
    <phone>+86-18829584958</phone>
    <email>weihonglianghaoren@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xijing Hospital ， Fourth Military Medical University</name>
      <address>
        <city>Xi`an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nanlin Li, Ph.D</last_name>
      <phone>+86-137-0911-3279</phone>
      <email>nanlin-74@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Hongliang Wei, Master</last_name>
      <phone>+86-186-2963-7040</phone>
      <email>weihonglianghaoren@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 9, 2013</lastchanged_date>
  <firstreceived_date>November 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital</investigator_affiliation>
    <investigator_full_name>LiNanlin,Ph.D, Chief Physician,Clinical Professor</investigator_full_name>
    <investigator_title>The department of Vascular endocrine surgery</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>TNBC（Triple Negative Breast Cancer）</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
